Sfondo Header
L'angolo del dottorino
Search the site... Advanced search
✖

Arterial hypertension: overview

Arterial hypertension is a condition characterized by a persistent increase in pressure within the systemic circulation that can, over time, contribute to cardiovascular, cerebrovascular and renal disease. It is not synonymous with a single measurement above normal, nor is it necessarily a symptomatic syndrome: identifying it requires reliable measurements, confirmation that the abnormality persists, and interpretation in the clinical context. Operational thresholds identify levels at which the balance of benefits and risks of intervention becomes favorable, whereas the biological relationship between blood pressure and vascular damage develops along a continuum, without an abrupt discontinuity at a conventional cutoff.

In the 2024 European Society of Cardiology classification,arterial hypertension retains an office threshold of at least 140 mmHg systolic or at least 90 mmHg diastolic. The category of elevated blood pressure instead comprises systolic readings of 120–139 mmHg or diastolic readings of 70–89 mmHg, provided neither component reaches the threshold for hypertension. This distinction enables recognition of a preventable risk before hypertension develops as conventionally defined. The 2025 US AHA/ACC guidelines use a different classification and define hypertension at systolic values of at least 130 mmHg or diastolic values of at least 80 mmHg; terminology must therefore always be accompanied by the classification system used.

The epidemiological burden is enormous. An analysis by the NCD Risk Factor Collaboration published in 2021 estimated that, in 2019, approximately 1.28 billion people aged 30–79 years had hypertension. A subsequent analysis published by O’Connell and colleagues in 2026 estimated for 2020 approximately 1.71 billion adults with hypertension, corresponding to 33.0% of the adult population considered. These two estimates do not describe an increase that occurred over a single year: they derive from different populations and estimation procedures. Both document the scale of the problem and the persistent gaps between disease prevalence, diagnostic awareness, treatment and blood pressure control.

Most cases are classified asprimary hypertension, in which genetic predisposition, environmental factors and changes in regulatory systems interact without a single identifiable cause. Insecondary hypertension , by contrast, an identifiable condition produces or sustains the elevation in blood pressure. The distinction is clinically crucial because some causes can be treated specifically and sometimes definitively, whereas merely lowering the readings may leave the underlying mechanism active.

Etiology, pathogenesis and pathophysiology

Arterial blood pressure results from the interaction between the volume of blood ejected by the heart, resistance in small vessels and the elastic properties of large arteries. At steady state, mean arterial pressure depends principally on the product of cardiac output and systemic vascular resistance, whereas systolic and pulse pressure are also influenced by ejection velocity, aortic compliance and reflected waves. This distinction explains why two people with similar brachial readings may have different combinations of hemodynamic abnormalities and different disease trajectories. The measured number is the end result of a regulatory system, not a complete description of how that system works.

In secondary forms, a more clearly defined causal sequence can be reconstructed. Renal parenchymal disease may limit sodium excretion and activate neurohormonal systems; hemodynamically significant renal artery stenosis may reduce the perfusion pressure sensed by the kidney and stimulate renin secretion; autonomous aldosterone excess increases distal sodium reabsorption and contributes to cardiovascular effects not entirely explained by blood pressure. Other causes include excess catecholamines or cortisol, certain thyroid diseases, aortic coarctation, and drugs or substances that influence blood pressure. The causes of secondary hypertension should be investigated in relation to their clinical probability and the likelihood of meaningfully changing treatment.

In primary hypertension, family history reflects a predominantly polygenicsusceptibility, modified by exposures throughout life. Age, weight gain and increased visceral adiposity, excessive sodium intake, inadequate dietary potassium, sedentary behavior and high alcohol consumption all contribute to risk, with varying importance between individuals. Family history does not make hypertension inevitable, and having no relatives with hypertension does not rule out a predisposition. Social circumstances, access to nutritious food, sleep disorders and access to healthcare also influence exposure and the ability to modify it; these cannot be reduced to a generalized lack of willpower on the patient's part.

The kidney plays a central role in long-term blood pressure maintenance through pressure natriuresis: increased perfusion pressure normally promotes sodium excretion, limiting extracellular volume and cardiac output. When sodium-excreting capacity is relatively reduced, the balance between intake and output may be achieved at a higher blood pressure. This does not mean that everyone with hypertension has obvious volume expansion: once a new steady state is established, sodium balance may return to equilibrium, but at a different blood pressure. Salt sensitivity describes individual variability in blood pressure responses to changes in sodium intake and cannot be identified by a single serum sodium measurement.

The renin–angiotensin–aldosterone system links renal perfusion, volume and vascular tone. Renin initiates the formation of angiotensin I; angiotensin-converting enzyme contributes to the production of angiotensin II, which acts through the AT1 receptor to promote vasoconstriction, aldosterone secretion and sodium retention. Aldosterone acts on the mineralocorticoid receptor, modifying the expression and activity of distal transport systems. Tissue effects also include growth and remodeling signals. Activation does not necessarily produce high circulating renin levels: several hypertensive phenotypes show low renin, and plasma concentrations are not equivalent to local activity.

The sympathetic nervous system can increase heart rate and myocardial contractility, arteriolar tone, renin release and renal sodium reabsorption. In obesity, signals from adipose tissue and alterations in central regulation interact with renal compression and increased tubular reabsorption. Leptin can contribute to sympathetic stimulation through hypothalamic circuits, whereas the relationship between insulin resistance and blood pressure is mediated by several pathways rather than a single hormone. These mechanisms help explain why weight loss can improve blood pressure even before irreversible organ damage occurs, without implying that every case of obesity or hypertension involves the same dominant disturbance.

The vascular wall is actively involved in this process. Reduced availability of nitric oxide limits endothelium-dependent vasodilation; oxidative stress, vasoconstrictor signals and extracellular matrix changes alter vascular tone and structure. In arterioles, luminal narrowing and remodeling increase resistance; in large arteries, loss of elasticity and increased stiffness raise pulsatile load. Longitudinal data indicate that aortic stiffness may precede the development of hypertension, as well as being worsened by exposure to elevated pressure. A bidirectional relationship thus develops in which initially functional changes can become established structural abnormalities.

The effect on organs depends on transmitted pressure, duration of exposure and autoregulatory capacity. The left ventricle responds to increased afterload with changes in mass and geometry; small cerebral and renal vessels are exposed to forces that can promote endothelial and microvascular damage. Pulse pressure becomes particularly important when large arteries lose their capacity to dampen the fluctuations generated by cardiac ejection. Thus, the disease is not simply a matter of excessive force exerted on blood vessels, but involves a progressive interaction among hemodynamic load, cellular responses, perfusion changes and tissue vulnerability.

Clinical manifestations and patient assessment

The most common presentation is theabsence of symptoms. Hypertension is detected during preventive checkups, consultations for other reasons, occupational assessments or home measurements. History-taking therefore starts by establishing how the reading was obtained: device used, rest conditions, cuff size, number of measurements, time of day, previous values and the presence of pain or stress. A patient reporting usually normal blood pressure may have measured it only over limited periods; conversely, a series of measurements performed under inappropriate conditions may create a false impression of persistent elevation. Longitudinal documentation is more informative than the highest remembered reading.

When headache, dizziness, tinnitus, palpitations or fatigue are reported, their course and temporal relationship to measurements must be reconstructed without automatically attributing them to elevated blood pressure. These symptoms are common and often nonspecific; pain or anxiety may themselves raise blood pressure. Moderately elevated blood pressure does not establish that a headache is “caused by blood pressure”. By contrast, focal neurological symptoms, altered mental status, persistent chest pain, severe dyspnea or acute visual disturbances require immediate assessment for possible organ damage, regardless of reassuring interpretations of previous episodes.

Personal history should cover the duration of elevated blood pressure, previous treatments, response and tolerability, any interruptions, pregnancy or the possibility of pregnancy, kidney disease, diabetes and cardiovascular events. Age at onset and speed of development guide the etiological investigation: early, sudden or rapidly worsening elevation may warrant particular attention to secondary causes. Family history distinguishes the simple occurrence of hypertension among relatives from very early-onset disease, stroke at a young age or familial endocrine disorders. This information modifies diagnostic probability without replacing the investigations needed to confirm a specific cause.

The review of exposures must include prescription medicines, over-the-counter products, supplements and recreational substances. Nonsteroidal anti-inflammatory drugs, glucocorticoids, some contraceptives, sympathomimetic decongestants, stimulants and licorice may contribute to elevated blood pressure. It is useful to ask how products are actually taken, not merely their names, because intermittent use and varying doses may be missed by a standard list. In someone already receiving treatment, adherence should be explored without judgment: adverse effects, cost, regimen complexity and failure to understand the asymptomatic nature of the disease may explain poor control better than true pharmacological ineffectiveness.

Sleep assessment addresses snoring, witnessed apneas, daytime sleepiness and unrefreshing sleep; renal assessment considers previous urinary abnormalities and known diseases. Episodes of palpitations, sweating and headache may suggest catecholamine excess, but their specificity is limited and context-dependent. Weight gain, muscle weakness, skin changes or thyroid-related symptoms are meaningful when they form a consistent pattern. Clinical reasoning therefore proceeds from the blood pressure finding to investigation of plausible associations, avoiding both indiscriminate screening and an automatic label of essential hypertension.

Physical examination includes standardized blood pressure measurement; assessment of pulse rate and rhythm, weight, height and fat distribution. Blood pressure in both arms is compared at the initial assessment; a persistent difference requires interpretation and the arm with the higher readings is generally used for subsequent checks. Assessment for orthostatic hypotension is particularly important in older adults, people with diabetes, those with postural symptoms and during treatment changes. A seated reading may appear adequate even though standing produces a symptomatic fall, affecting the balance between benefit and tolerability.

Cardiac and pulmonary auscultation, assessment of peripheral pulses and examination for vascular bruits or edema complete the evaluation. A femoral pulse that is diminished or delayed relative to the radial pulse may suggest coarctation; an abdominal bruit may increase suspicion of renovascular disease, but its absence does not exclude it. Signs of congestion or neurological or retinal abnormalities shift the focus from diagnosis of elevated blood pressure alone to establishing the clinical consequences. The physical examination may be completely normal even after years of exposure: normal findings do not rule out subclinical damage and do not obviate baseline testing.

Investigations, diagnosis and risk assessment

The diagnostic pathway begins by correcting sources of error. Measurement is performed with a validated device, a cuff appropriate to arm circumference, the patient seated and relaxed, back and arm supported, and feet on the floor. Recent exercise is avoided before measurement, and smoking and caffeine intake are taken into account; no conversation takes place during measurement. Repeated readings help reduce the effects of initial alerting and random variability. Standardization is not a formality: a few millimeters of mercury can change the classification of a patient close to a threshold and affect a decision that may remain in place for years.

In the absence of an urgent clinical presentation, diagnosis is generally not based on a single visit. According to European guidelines, persistent elevation should be documented by repeated office measurements and, when possible, confirmed outside the office. Home blood pressure monitoring collects measurements over several days in the usual environment; 24-hour ambulatory blood pressure monitoring records daily activities and sleep as well. The two methods complement each other: the former facilitates longitudinal verification, whereas the latter characterizes the circadian pattern and can identify abnormalities not apparent from morning and evening readings alone.

European reference thresholds for hypertension depend on the measurement method and are met when at least one of the two components reaches its respective limit. The same threshold therefore does not apply to office, home and nighttime readings.

Combining office and out-of-office measurements identifies distinct phenotypes. Inwhite-coat hypertension, in an untreated person, readings are hypertensive in the office but not outside it; inmasked hypertension the reverse is true. A nonhypertensive office average therefore does not guarantee normal exposure during work or sleep. Organ damage disproportionate to office values strengthens the case for investigating such a discrepancy. In treated patients, analogous patterns should be described as differences in control and not confused with the phenotypes of never-treated individuals.

After confirmation, baseline tests characterize renal function, metabolism and possible consequences of exposure. Creatinine with estimated glomerular filtration rate, sodium, potassium, blood glucose or glycated hemoglobin, lipid profile and urinalysis, supplemented by an assessment ofalbuminuria, help define risk and treatment safety. Electrocardiography investigates hypertrophy, arrhythmias and signs of heart disease, although it has limited sensitivity for some structural abnormalities. A normal test does not eliminate risk; an abnormal finding requires etiological interpretation because diabetes, cardiomyopathies or kidney diseases can cause similar abnormalities independently of blood pressure.

Further investigations address specific questions. Echocardiography characterizes mass, geometry, function and valves when clinically indicated; renal or vascular imaging and endocrine tests are selected according to the suspected condition. Screening for primary aldosteronism requires interpreting aldosterone and renin in light of potassium, medicines and sampling conditions, not reading an isolated numerical ratio. Sleep assessment may require dedicated tests. The rational sequence is therefore to confirm blood pressure, identify the phenotype, investigate damage and comorbidities, and then examine potential causes, without treating all second-line tests as mandatory for every patient.

The assessment of cardiovascular risk integrates age, sex, smoking, lipids, diabetes, kidney function, previous events and organ damage. In eligible individuals, SCORE2 and SCORE2-OP estimate European ten-year risk, calibrated by geographic region and age range. Existing documented cardiovascular disease should not be artificially reduced to a first-event risk estimate. In younger people, low ten-year risk can coexist with substantial anticipated lifetime exposure; in older adults, frailty and tolerability prevent the score alone from becoming an automatic treatment decision.

Treatment, follow-up and prognosis

Treatment aims to prevent events and preserve function and independence, not merely achieve a lower numerical reading. Nonpharmacological therapy addresses exposures that sustain elevated blood pressure and coexisting risk factors. Sodium reduction, a diet rich in plant-based foods, weight management, physical activity and alcohol limitation can be combined and adapted to the individual. Changes must be concrete and verifiable: identifying the main sources of salt in a person's usual diet is more useful than an abstract recommendation to eat “without salt”.

The DASH and DASH-Sodium studies demonstrated that dietary patterns and sodium intake affect blood pressure even without weight loss. Fruit, vegetables, legumes, whole grains and a favorable fat composition are parts of a comprehensive intervention; the effect does not derive from a single food with therapeutic properties. Dietary potassium may contribute to blood pressure control, but supplements and salt substitutes require caution when excretory capacity is reduced or medications that increase serum potassium are being taken. Prevention must preserve a favorable balance between blood pressure benefit and metabolic safety.

The weight reduction often lowers blood pressure in people with excess weight, but the response varies and does not justify automatically stopping effective treatment. Aerobic physical activity and appropriately adapted resistance exercise improve blood pressure and functional status; progression should match capacity, symptoms and comorbidities. Reducing alcohol intake is particularly beneficial when baseline consumption is high. Smoking cessation remains essential to overall cardiovascular risk, even if its effects on office blood pressure do not capture all its benefits. Sustained interventions have a different value from intense but short-lived changes.

The decision to start medication integrates confirmed blood pressure and the clinical profile. The benefit is well established in persistent hypertension; for elevated blood pressure below the European threshold, the indication depends primarily on risk and response to behavioral measures. Thetreatment algorithm must consistently follow the chosen guideline, without combining diagnostic thresholds from one document with treatment-decision thresholds from another. A less severe classification does not imply clinical insignificance, just as a diagnostic label does not necessarily require identical treatment for everyone sharing it.

The main components of pharmacological therapy are renin–angiotensin system blockers, calcium channel blockers, and thiazide or thiazide-like diuretics, selected and combined according to the individual clinical picture. Low-dose combinations can target complementary mechanisms; a single-pill combination may reduce regimen complexity. Beta-blockers retain important indications when particular cardiac conditions coexist. These drugs are not interchangeable in every circumstance: kidney function, electrolytes, bradycardia, edema, gout and pregnancy alter the balance of benefits and risks for individual classes.

Response must be checked through reliable measurements, symptoms, adherence and appropriate laboratory monitoring. Apparent treatment failure requires ruling out measurement errors, the white-coat effect, incomplete adherence and interfering substances before diagnosing resistant hypertension. The need for several medications may reflect complex disease but does not, by itself, demonstrate true resistance. Once confirmed, assessment for secondary causes and optimization of diuretic and add-on treatment become particularly important; procedures such as renal denervation are intended for selected patients and do not replace a proper definition of the problem.

Randomized trials show that lowering blood pressure reduces cardiovascular risk, but the absolute benefit depends on baseline risk. SPRINT demonstrated a benefit from intensive treatment in a selected high-risk population without diabetes or previous stroke, along with an increase in certain adverse events. The result cannot be automatically extrapolated to every patient or to readings obtained using different measurement techniques. In practice, the target should be reached with appropriate gradual adjustment and tolerability, recognizing symptomatic hypotension, electrolyte disturbances or worsening kidney function and modifying the plan when necessary.

Follow-up continues after initial control because weight, kidney function, concurrent treatments and behavior may change. Agreed home monitoring helps distinguish isolated fluctuations from persistent elevation and reduces reliance on improvised medication adjustments. Prognosis improves when control is sustained over time and other risk factors are managed; it remains influenced by damage already accumulated and by comorbidities. Blood pressure normalized by treatment demonstrates that the intervention works, not necessarily that the underlying predisposition requiring it has disappeared.

Complications and significance of organ damage

Complications develop through macrovascular, microvascular and cardiac pathways that often coexist. Organ damage may precede symptoms and identifies biologically meaningful exposure, but it is not synonymous with an established clinical event. Ventricular hypertrophy, albuminuria and subclinical vascular changes influence risk stratification; myocardial infarction, stroke and heart failure are clinical manifestations with further consequences. This distinction avoids describing every early finding as an irreversible complication and allows recognition that some changes may regress with effective treatment.

Among the cardiac complications, increased afterload promotes hypertrophy and impaired ventricular relaxation. The increase in myocardial mass is not always matched by the microvascular network and may be accompanied by fibrosis and reduced coronary reserve. Together, these changes may predispose to ischemia, heart failure with preserved ejection fraction and, through other disease trajectories, systolic dysfunction. Increased filling pressures and atrial remodeling contribute to atrial fibrillation, which adds thromboembolic risk and further changes management.

In the brain, small-vessel disease can produce deep ischemic lesions, white matter changes and microbleeds. Neurological complications include ischemic and hemorrhagic stroke and a contribution to vascular cognitive impairment. The mechanisms are not identical: large-vessel atherosclerosis, arteriolopathy, embolism in the presence of atrial fibrillation and vessel wall fragility may contribute to varying degrees. Blood pressure control is a fundamental component of prevention, but management during an acute neurological event follows specific protocols and is not the same as chronic management.

The kidney is both regulator and target. Prolonged exposure may injure arterioles and glomeruli, promote nephron loss and reduce filtration; worsening kidney function, in turn, makes sodium excretion more difficult. The diagnosis of hypertensive nephropathy should not, however, be made solely because hypertension and kidney failure coexist. Marked proteinuria, hematuria, rapid deterioration or other atypical features warrant consideration of alternative etiologies. Albuminuria is also a marker of systemic cardiovascular risk, not merely of injury confined to the kidney.

The retina offers an opportunity to observe the microcirculation directly. Hypertensive retinopathy encompasses findings of varying significance, from chronic arteriolar changes to hemorrhages, exudates and severe abnormalities in acute settings. Some mild signs have limited specificity and are influenced by age and other diseases, whereas advanced findings may help identify severe damage. Their significance must therefore be interpreted in light of the degree and course of blood pressure elevation, visual symptoms and neurological or renal findings, avoiding automatic equivalence between a single sign and a particular duration of disease.

In large arteries, hypertension and atherosclerosis share and amplify some risks. Vascular complications include coronary and peripheral events and a contribution to aortic disease. Dissection is not simply the mechanical consequence of a single spike: wall integrity, predispositions and pre-existing aortic disease influence risk. This complexity makes it necessary to distinguish long-term prevention from the response to acute pain or signs of ischemia, which require immediate evaluation even in people without a previous diagnosis of hypertension.

A hypertensive emergency is defined by a marked blood pressure elevation accompanied by acute organ damage, not by a numerical threshold alone. Encephalopathy, pulmonary edema, acute aortic syndromes or other manifestations require monitored treatment and targets specific to the clinical condition. In the absence of acute damage, very high blood pressure still requires prompt assessment, but rapid, indiscriminate reduction can compromise perfusion. The common principle is to identify which organ is threatened and the appropriate speed of correction, rather than treating only the sphygmomanometer display.

Finally, treatment itself may produce complications that must be distinguished from those of the disease: hypotension, syncope, electrolyte abnormalities and acute kidney injury depend on medications, doses, comorbidities and intercurrent conditions. Prevention requires reassessment during dehydration, acute illness or changes in kidney function. The favorable prognostic balance of treatment does not eliminate the need for monitoring; conversely, fear of adverse effects does not justify maintaining persistently harmful blood pressure. Ongoing management combines prevention of exposure-related consequences with early recognition of each patient's limits of tolerability.

References
  1. McEvoy JW et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. European Heart Journal. 2024;45(38):3912–4018.
  2. Mancia G et al. 2023 ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension. Journal of Hypertension. 2023;41(12):1874–2071.
  3. Jones DW et al. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2025;152(11):e114–e218.
  4. Oparil S et al. Hypertension. Nature Reviews Disease Primers. 2018;4:18014.
  5. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. The Lancet. 2021;398(10304):957–980.
  6. O’Connell SS et al. Global Hypertension 2000 to 2020: Trends, Disparities, and Progress in Awareness, Treatment, and Control. Journal of the American College of Cardiology. 2026;87(18):2338–2351.
  7. Lewington S et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. The Lancet. 2002;360(9349):1903–1913.
  8. Muntner P et al. Measurement of Blood Pressure in Humans: A Scientific Statement From the American Heart Association. Hypertension. 2019;73(5):e35–e66.
  9. Stergiou GS et al. 2021 European Society of Hypertension practice guidelines for office and out-of-office blood pressure measurement. Journal of Hypertension. 2021;39(7):1293–1302.
  10. Parati G et al. Home blood pressure monitoring: methodology, clinical relevance and practical application: a 2021 position paper by the Working Group on Blood Pressure Monitoring and Cardiovascular Variability of the European Society of Hypertension. Journal of Hypertension. 2021;39(9):1742–1767.
  11. Hall JE et al. Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. Circulation Research. 2015;116(6):991–1006.
  12. Kaess BM et al. Aortic stiffness, blood pressure progression, and incident hypertension. JAMA. 2012;308(9):875–881.
  13. SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. European Heart Journal. 2021;42(25):2439–2454.
  14. SCORE2-OP working group and ESC Cardiovascular risk collaboration. SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions. European Heart Journal. 2021;42(25):2455–2467.
  15. SPRINT Research Group. Final Report of a Trial of Intensive versus Standard Blood-Pressure Control. The New England Journal of Medicine. 2021;384(20):1921–1930.
  16. Blood Pressure Lowering Treatment Trialists’ Collaboration. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. The Lancet. 2021;397(10285):1625–1636.
  17. Appel LJ et al. A clinical trial of the effects of dietary patterns on blood pressure. The New England Journal of Medicine. 1997;336(16):1117–1124.
  18. Sacks FM et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. The New England Journal of Medicine. 2001;344(1):3–10.
  19. Edwards JJ et al. Exercise training and resting blood pressure: a large-scale pairwise and network meta-analysis of randomised controlled trials. British Journal of Sports Medicine. 2023;57(20):1317–1326.
  20. Neter JE et al. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension. 2003;42(5):878–884.
  21. Roerecke M et al. The effect of a reduction in alcohol consumption on blood pressure: a systematic review and meta-analysis. The Lancet Public Health. 2017;2(2):e108–e120.

Informational notice: the information contained on this page is provided solely for informational and educational purposes and does not replace the advice, diagnosis or treatment provided by a physician. If needed, always consult a qualified healthcare professional.

Artificial intelligence transparency: this page was created with the support of artificial intelligence tools, used to assist in the production and processing of its content.